Lenetix Medical Screening Laboratory to Co-Market CombiMatrix Molecular Diagnostics' Suite of Developmental Genomics Array-Based Tests

MUKILTEO, Wash., Jan. 26, 2009 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that its wholly owned subsidiary, Combimatrix Molecular Diagnostics (CMDX), has entered into a new partnership with Lenetix, a New York based laboratory, to co-market CMDX's suite of array CGH based tests including the industry leading BAC HD Scan(tm) test, the most comprehensive test for characterizing genomic causes of childhood developmental disorders. The BAC HD Scan test can identify over 290 genomic causes of developmental disorders and is routinely used in postnatal genetic diagnostics. Also included in CMDX's suite of developmental genomic tests is the Prenatal Scan array CGH test, a more customized test specifically designed and validated for use in prenatal genetic diagnostics. Both companies will launch their co-marketing endeavors at the upcoming Society of Maternal-Fetal Medicine 29th Annual Meeting in San Diego (Jan 26-30th, 2009).